Zanubrutinib (new indication: marginal zone lymphoma (MLZ), ≥ 1 prior anti-CD20-antibody-based therapy)

Subject:

• Active Substance: Zanubrutinib
• Name: Brukinsa®
• Therapeutic area: Marginal zone lymphoma (MZL)
• Pharmaceutical company: BeiGene Germany GmbH

Time table:

• Start: 15.12.2022
• Final decision by G-BA: 15.06.2023

Final decision:

• No additional benefit proved